HOTH THERAPEUTICS INC (HOTH)
US44148G2049 - Common Stock
Overall HOTH gets a fundamental rating of 2 out of 10. We evaluated HOTH against 193 industry peers in the Pharmaceuticals industry. HOTH has a great financial health rating, but its profitability evaluates not so good. HOTH does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
HOTH had negative earnings in the past year.
HOTH had a negative operating cash flow in the past year.
HOTH had negative earnings in each of the past 5 years.
HOTH had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
With a Return On Assets value of -90.37%, HOTH is not doing good in the industry: 75.79% of the companies in the same industry are doing better.
HOTH has a Return On Equity of -100.18%. This is comparable to the rest of the industry: HOTH outperforms 40.53% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -90.37% | ||
| ROE | -100.18% | ||
| ROIC | N/A |
ROA(3y)-126.94%
ROA(5y)-157.87%
ROE(3y)-151.97%
ROE(5y)-186.32%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
HOTH does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
HOTH has more shares outstanding than it did 1 year ago.
HOTH has more shares outstanding than it did 5 years ago.
HOTH has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
Based on the Altman-Z score of -7.69, we must say that HOTH is in the distress zone and has some risk of bankruptcy.
HOTH's Altman-Z score of -7.69 is on the low side compared to the rest of the industry. HOTH is outperformed by 68.42% of its industry peers.
HOTH has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -7.69 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
A Current Ratio of 10.16 indicates that HOTH has no problem at all paying its short term obligations.
With an excellent Current ratio value of 10.16, HOTH belongs to the best of the industry, outperforming 83.16% of the companies in the same industry.
HOTH has a Quick Ratio of 10.16. This indicates that HOTH is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of HOTH (10.16) is better than 83.16% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 10.16 | ||
| Quick Ratio | 10.16 |
3. Growth
3.1 Past
HOTH shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 72.91%, which is quite impressive.
EPS 1Y (TTM)72.91%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%48.33%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
Based on estimates for the next years, HOTH will show a very strong growth in Earnings Per Share. The EPS will grow by 20.12% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y45.34%
EPS Next 2Y30.17%
EPS Next 3Y20.12%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for HOTH. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for HOTH. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as HOTH's earnings are expected to grow with 20.12% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y30.17%
EPS Next 3Y20.12%
5. Dividend
5.1 Amount
No dividends for HOTH!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
HOTH THERAPEUTICS INC
NASDAQ:HOTH (12/20/2024, 8:17:00 PM)
Premarket: 0.78 -0.03 (-3.7%)0.81
+0.04 (+5.21%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners5.05%
Inst Owner Change-29.85%
Ins Owners0.93%
Ins Owner Change0.53%
Market Cap5.59M
Analysts82.5
Price Target4.59 (466.67%)
Short Float %6.7%
Short Ratio0.38
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)27.95%
Min EPS beat(2)10.61%
Max EPS beat(2)45.28%
EPS beat(4)3
Avg EPS beat(4)22.37%
Min EPS beat(4)-4.88%
Max EPS beat(4)45.28%
EPS beat(8)6
Avg EPS beat(8)17.25%
EPS beat(12)9
Avg EPS beat(12)14.53%
EPS beat(16)11
Avg EPS beat(16)7.34%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)12.5%
PT rev (3m)12.5%
EPS NQ rev (1m)0%
EPS NQ rev (3m)29.07%
EPS NY rev (1m)3.54%
EPS NY rev (3m)1.17%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.75 | ||
| P/tB | 0.75 | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.33
EYN/A
EPS(NY)-0.72
Fwd EYN/A
FCF(TTM)-1.16
FCFYN/A
OCF(TTM)-1.16
OCFYN/A
SpS0
BVpS1.09
TBVpS1.09
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -90.37% | ||
| ROE | -100.18% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-126.94%
ROA(5y)-157.87%
ROE(3y)-151.97%
ROE(5y)-186.32%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 10.16 | ||
| Quick Ratio | 10.16 | ||
| Altman-Z | -7.69 |
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)72.91%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%48.33%
EPS Next Y45.34%
EPS Next 2Y30.17%
EPS Next 3Y20.12%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y19.98%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y25.35%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y24.72%
OCF growth 3YN/A
OCF growth 5YN/A